DAPT Score to decide on utility of prolonged dual antiplatelet therapy
DAPT score is based on the Dual Antiplatelet Therapy Study  and is used to assess the risk/benefit ratio of prolonged dual antiplatelet therapy. Advanced age is given a negative score as it increases the bleeding risk. Age of 75 or above is given two points while age between 65-74 years is given 1 point. Current smoking, diabetes mellitus, myocardial infarction at presentation, previous percutaneous intervention (PCI) or myocardial infarction, stent diameter of less than 3 mm and Paclitaxel eluting stent, all get 1 point each. Congestive heart failure or left ventricular ejection fraction less than 30% and saphenous vein graft PCI get 2 points each. If the total score is 2 or more, the benefit/risk ratio for prolonged dual antiplatelet therapy is favourable. DAPT score below 2 is associated with an unfavourable benefit/risk ratio.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66.